Cargando…
A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies
In the recent years researchers have put a lot of emphasis on the possible immunotherapeutic strategies able to target tumors. Many studies have proven that the key role in recognition and eradication of cancer cells, both for mice and humans, is being conducted by the invariant natural killer T-cel...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Polish Society of Experimental and Clinical Immunology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573892/ https://www.ncbi.nlm.nih.gov/pubmed/28860937 http://dx.doi.org/10.5114/ceji.2017.69361 |
_version_ | 1783259732265402368 |
---|---|
author | Waldowska, Małgorzata Bojarska-Junak, Agnieszka Roliński, Jacek |
author_facet | Waldowska, Małgorzata Bojarska-Junak, Agnieszka Roliński, Jacek |
author_sort | Waldowska, Małgorzata |
collection | PubMed |
description | In the recent years researchers have put a lot of emphasis on the possible immunotherapeutic strategies able to target tumors. Many studies have proven that the key role in recognition and eradication of cancer cells, both for mice and humans, is being conducted by the invariant natural killer T-cells (NKT). This small subpopulation of lymphocytes can kill other cells, either directly or indirectly, through the natural killer cells’ (NK) activation. They can also swiftly release cytokines, causing the involvement of elements of the innate and acquired immune system. With the discovery of α-galactosylceramide (α-GalCer) – the first known agonist for iNKT cells – and its later subsequent analogs, it became possible to effectively stimulate iNKT cells, hence to keep control over the tumor progression. This article refers to the current knowledge concerning iNKT cells and the most important aspects of their antitumor activity. It also highlights the clinical trials that aim at increasing the amount of iNKT cells in general and in the microenvironment of the tumor. For sure, the iNKT-based immunotherapeutic approach holds a great potential and is highly probable to become a part of the cancer immunotherapy in the future. |
format | Online Article Text |
id | pubmed-5573892 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Polish Society of Experimental and Clinical Immunology |
record_format | MEDLINE/PubMed |
spelling | pubmed-55738922017-08-31 A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies Waldowska, Małgorzata Bojarska-Junak, Agnieszka Roliński, Jacek Cent Eur J Immunol Review Paper In the recent years researchers have put a lot of emphasis on the possible immunotherapeutic strategies able to target tumors. Many studies have proven that the key role in recognition and eradication of cancer cells, both for mice and humans, is being conducted by the invariant natural killer T-cells (NKT). This small subpopulation of lymphocytes can kill other cells, either directly or indirectly, through the natural killer cells’ (NK) activation. They can also swiftly release cytokines, causing the involvement of elements of the innate and acquired immune system. With the discovery of α-galactosylceramide (α-GalCer) – the first known agonist for iNKT cells – and its later subsequent analogs, it became possible to effectively stimulate iNKT cells, hence to keep control over the tumor progression. This article refers to the current knowledge concerning iNKT cells and the most important aspects of their antitumor activity. It also highlights the clinical trials that aim at increasing the amount of iNKT cells in general and in the microenvironment of the tumor. For sure, the iNKT-based immunotherapeutic approach holds a great potential and is highly probable to become a part of the cancer immunotherapy in the future. Polish Society of Experimental and Clinical Immunology 2017-08-08 2017 /pmc/articles/PMC5573892/ /pubmed/28860937 http://dx.doi.org/10.5114/ceji.2017.69361 Text en Copyright: © 2017 Polish Society of Experimental and Clinical Immunology http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Review Paper Waldowska, Małgorzata Bojarska-Junak, Agnieszka Roliński, Jacek A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies |
title | A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies |
title_full | A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies |
title_fullStr | A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies |
title_full_unstemmed | A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies |
title_short | A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies |
title_sort | brief review of clinical trials involving manipulation of invariant nkt cells as a promising approach in future cancer therapies |
topic | Review Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573892/ https://www.ncbi.nlm.nih.gov/pubmed/28860937 http://dx.doi.org/10.5114/ceji.2017.69361 |
work_keys_str_mv | AT waldowskamałgorzata abriefreviewofclinicaltrialsinvolvingmanipulationofinvariantnktcellsasapromisingapproachinfuturecancertherapies AT bojarskajunakagnieszka abriefreviewofclinicaltrialsinvolvingmanipulationofinvariantnktcellsasapromisingapproachinfuturecancertherapies AT rolinskijacek abriefreviewofclinicaltrialsinvolvingmanipulationofinvariantnktcellsasapromisingapproachinfuturecancertherapies AT waldowskamałgorzata briefreviewofclinicaltrialsinvolvingmanipulationofinvariantnktcellsasapromisingapproachinfuturecancertherapies AT bojarskajunakagnieszka briefreviewofclinicaltrialsinvolvingmanipulationofinvariantnktcellsasapromisingapproachinfuturecancertherapies AT rolinskijacek briefreviewofclinicaltrialsinvolvingmanipulationofinvariantnktcellsasapromisingapproachinfuturecancertherapies |